TABLE 1.

Distribution of animals across experimental groups (N = 59).

Sex	Genotype	Group	15 weeks (n)	28 weeks (n)	42 weeks (n)
Females	Wild type	WT	14	10	5
	Transgenic	5xFAD (Hem)	15	10	5
Males	Wild type	WT	16	12	7
	Transgenic	5xFAD (Hem)	14	10	6
Total			59	42	23

N, total number of unique individual animals enrolled at the baseline of the study; n, number of active subjects evaluated at a specific lifetime milestone. The sequential reduction in sample size (n) within the cohorts across successive time points was driven by a predefined, staggered tissue-harvesting protocol. Specifically, a designated subgroup of animals (n = 10 per sex/genotype) was pre-allocated for sacrifice immediately following behavioral tracking at the 15 and 28-week milestones to harvest brain tissues for parallel histological, morphological, and immunohistochemical (IHC) analyses. Natural mortality characteristic of advanced neurodegenerative pathology in the 5xFAD line contributed to the sample size reduction.